SCHEMBL1901356

SCHEMBL1901356

COc1ccc2nc(-c3nonc3N)[nH]c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.60
ALDH1A1 P00352 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
NPSR1 Q6W5P4 1/20 0.60
NPC1 O15118 4/20 0.60
TP53 P04637 4/20 0.60
MEN1 O00255 2/20 0.60
POLB P06746 2/20 0.60
PKM P14618 2/20 0.60
KMT2A Q03164 2/20 0.60
LMNA P02545 1/20 0.60
RPS6KA5 O75582 2/20 0.56
RAB9A P51151 3/20 0.56
HTT P42858 1/20 0.56
KDM4E B2RXH2 1/20 0.56
TSHR P16473 1/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
HSD17B10 Q99714 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1901354 0.90 SMN1; SMN2 (0.60) HPGDALDH1A1SMN1; SMN2NPSR1NPC1
SCHEMBL26921422 0.82 ALDH1A1 (0.65) HPGDALDH1A1SMN1; SMN2NPSR1NPC1
SCHEMBL14364609 0.81 ALDH1A1 (0.56) HPGDALDH1A1SMN1; SMN2NPSR1NPC1
SCHEMBL6401549 0.80 ALDH1A1 (0.65) HPGDALDH1A1SMN1; SMN2NPSR1RPS6KA5
SCHEMBL14364577 0.76 HPGD (0.60) HPGDALDH1A1SMN1; SMN2NPSR1NPC1
SCHEMBL1160565 0.76 ALDH1A1 (1.00) HPGDALDH1A1SMN1; SMN2NPSR1NPC1
SCHEMBL20982659 0.75 NPC1 (0.85) HPGDALDH1A1SMN1; SMN2NPC1TP53
SCHEMBL6243395 0.75 NPC1 (1.00) HPGDALDH1A1SMN1; SMN2NPC1TP53
SCHEMBL1902418 0.74 ALDH1A1 (0.65) HPGDALDH1A1SMN1; SMN2NPSR1NPC1
SCHEMBL216242 0.74 NPC1 (0.63) HPGDALDH1A1SMN1; SMN2NPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322521-B1 Heteroaryl compounds useful as inhibitors of GSK-3 VERTEX PHARMA (US) 2013-09-04 EP disclosed
EP-2322521-A1 Heteroaryl compounds useful as inhibitors of GSK-3 Vertex Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed
US-20070270420-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed
EP-1472245-A2 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 Vertex Pharmaceuticals Incorporated (US) 2004-11-03 EP disclosed
US-20040034037-A1 Heteroaryl compounds useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS, INCORPORATED 2004-02-19 US disclosed
WO-2003066629-A2 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270420-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 GSK3B, GSK3A, GSKIP HPGD 2444/4885ALDH1A1 3514/4885SMN1; SMN2 3347/4885
US-20040034037-A1 Heteroaryl compounds useful as inhibitors of GSK-3 GSK3B, GSK3A, GSKIP HPGD 2444/4885ALDH1A1 3514/4885SMN1; SMN2 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.